Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Vivos Therapeutics, Inc. (VVOS : NSDQ)
 
 • Company Description   
Vivos Therapeutics Inc. is a medical technology company. It engages in the development and commercialization of technology solutions for patients with sleep disordered breathing comprising mild-to-moderate obstructive sleep apnea. Vivos Therapeutics Inc. is based in Highlands Ranch, Colorado.

Number of Employees: 109

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.47 Daily Weekly Monthly
20 Day Moving Average: 135,738 shares
Shares Outstanding: 7.50 (millions)
Market Capitalization: $26.04 (millions)
Beta: 7.02
52 Week High: $7.95
52 Week Low: $1.98
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -24.73% -26.05%
12 Week 39.92% 27.10%
Year To Date -19.11% -24.24%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
7921 SOUTHPARK PLAZA SUITE 210
-
LITTLETON,CO 80120
USA
ph: 844-672-4357
fax: -
investors@vivoslife.com http://www.vivos.com
 
 • General Corporate Information   
Officers
R. Kirk Huntsman - Chief Executive Officer; Co-founder and Chairman o
Bradford Amman - Chief Financial Officer
Ralph E. Green - Director
Anja Krammer - Director
Mark F. Lindsay - Director

Peer Information
Vivos Therapeutics, Inc. (GSAC)
Vivos Therapeutics, Inc. (CASI)
Vivos Therapeutics, Inc. (ALCD.)
Vivos Therapeutics, Inc. (OMNN)
Vivos Therapeutics, Inc. (CGPI.)
Vivos Therapeutics, Inc. (CATX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-DRUGS
Sector: Medical
CUSIP: 92859E207
SIC: 3841
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/13/25
Share - Related Items
Shares Outstanding: 7.50
Most Recent Split Date: 10.00 (0.04:1)
Beta: 7.02
Market Capitalization: $26.04 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.35 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.54 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/13/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.46
Price/Cash Flow: -
Price / Sales: 1.81
EPS Growth
vs. Year Ago Period: 8.33%
vs. Previous Quarter: -22.22%
Sales Growth
vs. Year Ago Period: -5.77%
vs. Previous Quarter: 26.66%
ROE
06/30/25 - -232.76
03/31/25 - -170.43
12/31/24 - -197.55
ROA
06/30/25 - -84.30
03/31/25 - -77.82
12/31/24 - -76.43
Current Ratio
06/30/25 - 1.05
03/31/25 - 0.77
12/31/24 - 1.50
Quick Ratio
06/30/25 - 1.05
03/31/25 - 0.77
12/31/24 - 1.50
Operating Margin
06/30/25 - -99.49
03/31/25 - -76.82
12/31/24 - -74.09
Net Margin
06/30/25 - -99.49
03/31/25 - -76.82
12/31/24 - -74.09
Pre-Tax Margin
06/30/25 - -99.49
03/31/25 - -76.82
12/31/24 - -74.09
Book Value
06/30/25 - 0.78
03/31/25 - 0.75
12/31/24 - 1.35
Inventory Turnover
06/30/25 - -
03/31/25 - -
12/31/24 - -
Debt-to-Equity
06/30/25 - 1.69
03/31/25 - 0.00
12/31/24 - 0.00
Debt-to-Capital
06/30/25 - 62.87
03/31/25 - 0.00
12/31/24 - 0.00
 

Powered by Zacks Investment Research ©